BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37169162)

  • 21. Two Distinct Cdc2 Pools Regulate Cell Cycle Progression and the DNA Damage Response in the Fission Yeast S.pombe.
    Caspari T; Hilditch V
    PLoS One; 2015; 10(7):e0130748. PubMed ID: 26131711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.
    Diab A; Gem H; Swanger J; Kim HY; Smith K; Zou G; Raju S; Kao M; Fitzgibbon M; Loeb KR; Rodriguez CP; Méndez E; Galloway DA; Sidorova JM; Clurman BE
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28287-28296. PubMed ID: 33093209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited.
    Potapova TA; Sivakumar S; Flynn JN; Li R; Gorbsky GJ
    Mol Biol Cell; 2011 Apr; 22(8):1191-206. PubMed ID: 21325631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
    Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
    Sarwar S; Morozov VM; Purayil H; Daaka Y; Ishov AM
    Cell Death Dis; 2022 Oct; 13(10):868. PubMed ID: 36229449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells.
    Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. βArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
    Purayil HT; Daaka Y
    Prostate; 2022 May; 82(7):816-825. PubMed ID: 35226379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cdk1-dependent regulation of the mitotic inhibitor Wee1.
    Harvey SL; Charlet A; Haas W; Gygi SP; Kellogg DR
    Cell; 2005 Aug; 122(3):407-20. PubMed ID: 16096060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory phosphorylation of a mitotic cyclin-dependent kinase regulates the morphogenesis, cell size and virulence of the smut fungus Ustilago maydis.
    Sgarlata C; Pérez-Martín J
    J Cell Sci; 2005 Aug; 118(Pt 16):3607-22. PubMed ID: 16046476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Wee1 checkpoint inhibits anaphase onset.
    Lianga N; Williams EC; Kennedy EK; Doré C; Pilon S; Girard SL; Deneault JS; Rudner AD
    J Cell Biol; 2013 Jun; 201(6):843-62. PubMed ID: 23751495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.
    Ravindran Menon D; Luo Y; Arcaroli JJ; Liu S; KrishnanKutty LN; Osborne DG; Li Y; Samson JM; Bagby S; Tan AC; Robinson WA; Messersmith WA; Fujita M
    Cancer Res; 2018 Dec; 78(23):6561-6574. PubMed ID: 30297536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
    Ta HQ; Ivey ML; Frierson HF; Conaway MR; Dziegielewski J; Larner JM; Gioeli D
    Cancer Res; 2015 Dec; 75(23):5093-105. PubMed ID: 26573794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.